The uptake of influenza and pneumococcal vaccination among immunocompromised patients attending rheumatology outpatient clinics

Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency

“…Literature review highlights three main findings supported by our study: vaccine coverage rates against influenza and pneumococcus are always suboptimal (from 34% to 63% and from 11%% to 39%, respectively) [36][37][38][39][40]; pneumococcal vaccination uptakes are lower than influenza vaccine uptakes; and vaccine uptake rates vary according to disease groups [35,[41][42][43].…”

“…The reported rate of vaccination against pneumococcus was 49% (95%CI [47][48][49][50]); 51% (95%CI [49-53]) in the AI group, 36% (95%CI [30][31][32][33][34][35][36][37][38][39][40][41][42][43]) in the Tx group and 39% (95%CI [33][34][35][36][37][38][39][40][41][42][43][44]) in the MBD group (Table 3).…”

Infection and Infection Prevention in Patients Treated with Immunosuppressive Medications for Autoimmune Bullous Disorders

“…However, physician lack of familiarity with vaccine protocols in immunocompromised patients can lead to missed opportunities to immunize these patients. [46][47][48] Although recent general immunization guidelines have been published, 48 the most up-to-date vaccination information can be found on the Centers for Disease Control Web site (www.cdc.gov).…”

Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial

“…Guidelines from the Centers for Disease Control and Prevention (CDC), the American College of Rheumatology, and the European League Against Rheumatism recommend pneumococcal vaccination for patients who are receiving immunosuppressive therapy (1–3). Prior studies have shown that the rates of pneumococcal vaccination in immunosuppressed patients are low, ranging from 19% to 54% among patients with rheumatic disease (4–9). Although the current care regimen that is provided to patients with rheumatic disease during the office visit is often complex—e.g., assessment of functional status and disease activity indices, initiation and management of immunosuppressive medications, and acquisition and synthesis of laboratory and radiology data—pneumococcal vaccination should remain an essential part of patient care.…”